Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 5/20 | 0.51 |
| ▸ | HTR3A | P46098 | 3/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 3/20 | 0.47 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.47 |
| ▸ | HTR3B | O95264 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | NCF1 | P14598 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38664325 | 0.84 | ADRB1 (0.59) | ADRB1HTR3ADRD2DRD3HTR1A | |
| SCHEMBL630979 | 0.84 | ADRB1 (0.59) | ADRB1HTR3ADRD2DRD3HTR1A | |
| Hydrochloric Acid SCHEMBL631231 | 0.83 | ADRB1 (0.58) | ADRB1HTR3ADRD2DRD3HTR1A | |
| SCHEMBL5340480 | 0.75 | ADRB1 (0.56) | ADRB1HTR3ADRD2DRD3HTR1A | |
| SCHEMBL29197334 | 0.75 | RBP4 (0.49) | ADRB1HTR3ADRD2DRD3HTR1A | |
| SCHEMBL17300889 | 0.74 | HTR6 (0.44) | ADRB1HTR3ADRD2DRD3HTR1A | |
| SCHEMBL6716435 | 0.72 | ADRB1 (0.63) | ADRB1HTR3ADRD2DRD3HTR1A | |
| SCHEMBL9790141 | 0.72 | ADRB1 (0.63) | ADRB1HTR3ADRD2DRD3HTR1A | |
| SCHEMBL22432016 | 0.72 | ADRB1 (0.53) | ADRB1HTR3ADRD2DRD3HTR1A | |
| SCHEMBL15834279 | 0.71 | ADRB1 (0.75) | ADRB1HTR3ADRD2DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2021-02-11 | — | — | US | claimed |
| EP-3765082-A1 | USES, COMPOSITIONS AND METHODS | Fisahn, André (SE) | 2021-01-20 | — | — | EP | claimed |
| WO-2019175395-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2019-09-19 | — | — | WO | claimed |
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2021-02-11 | — | — | US | disclosed |
| EP-3765082-A1 | USES, COMPOSITIONS AND METHODS | Fisahn, André (SE) | 2021-01-20 | — | — | EP | disclosed |
| WO-2019175395-A1 | USES, COMPOSITIONS AND METHODS | FISAHN ANDRE (SE) | 2019-09-19 | — | — | WO | disclosed |
| WO-2009132454-A8 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2010-01-28 | — | — | WO | disclosed |
| WO-2009132454-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132454-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270413-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038589-A1 | USES, COMPOSITIONS AND METHODS | APP, CACNA1G, CACNA1B | ADRB1 1403/4885HTR3A 970/4885DRD2 3952/4885 |
| US-20090270413-A1 | DI-T-BUTYLPHENYL PIPERAZINES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1C, CACNA1I | ADRB1 229/4885HTR3A 829/4885DRD2 389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.